Since recombinant human endostatin (rh-endostatin;Endostar) has been listed 5 years,clinicians have combined it with chemotherapy for the treatment of lung cancers and other malignant tumors,and proved its effect and safety.A number of scholars have explored the application of Endostar alone or in combination with chemotherapy for treatment of malignant serous effusion,finding its high efficiency and low toxicity;and that hydrops controlling is stronger,and that it can significantly improve patients’ quality of life.It is worthy of conducting prospective,randomized and multi-center clinical studies and basic researches to clarify the mechanism. Since recombinant human endostatin (rh-endostatin; Endostar) has been listed 5 years, clinicians have combined it with chemotherapy for the treatment of lung cancers and other malignant tumors, and demonstrated its effect and safety. A number of scholars have explored the application of Endostar alone or in combination with chemotherapy for treatment of malignant serous effusion, finding its high efficiency and low toxicity; and that hydrops controlling is stronger, and that it can significantly improve patients’ quality of life. It is worthy of conducting prospective, randomized and multi-center clinical studies and basic researches to clarify the mechanism.